What Is Stenosis of the Heart? Causes & Treatment

Stenosis of the heart refers to a narrowing of one or more of the heart’s valves, restricting blood flow and forcing the heart to work harder to push blood through. The most commonly affected valve is the aortic valve, but stenosis can develop in the mitral, tricuspid, or pulmonary valve as well. Causes range from age-related calcium buildup and rheumatic fever to congenital defects present from birth, and the condition can stay silent for years before producing symptoms like breathlessness, chest pain, or fainting.

How Heart Valve Stenosis Works

Your heart has four valves that open and close with each heartbeat to keep blood flowing in one direction. When a valve becomes stenotic, its leaflets stiffen, thicken, or fuse together so they no longer open fully. The resulting bottleneck means the chamber behind the narrowed valve has to generate more pressure to push blood through. Over time, that extra workload changes the shape and function of the heart muscle itself.

In aortic stenosis, the left ventricle thickens its walls to compensate for the increased resistance. A cardiac MRI study of patients with severe aortic stenosis found that concentric hypertrophy and remodeling were the predominant patterns of adaptation, present in roughly seven out of ten patients.¹ That thickening helps maintain pumping strength for a while, but eventually the muscle stiffens, filling pressure rises, and fluid backs up into the lungs. The same general sequence plays out with mitral stenosis, though there the left atrium bears the brunt, stretching and eventually transmitting pressure backward into the lung circulation.

Which Valves Are Affected and Why

Aortic stenosis is the form you hear about most in high-income countries, and the dominant cause in older adults is calcification. Researchers once assumed calcium simply accumulated passively on aging valve tissue, the way mineral deposits build up in old pipes. That view has been overturned. The process is actively regulated by bone-forming cells that appear on valve leaflets, driving calcification through biological pathways rather than passive wear and tear.² Understanding this shift matters because it opens the door to drug therapies that might slow the process, rather than simply waiting until a valve needs replacement.

Mitral stenosis tells a different geographic story. In wealthier nations, it can result from aging and calcification or, less commonly, from radiation therapy or certain medications. Globally, though, rheumatic fever remains by far the leading cause. Rheumatic heart disease affects roughly 41 million people worldwide, predominantly in low- and middle-income countries.³ The infection triggers an immune response that scars and fuses the mitral valve leaflets over years, eventually narrowing the opening.

Stenosis of the tricuspid or pulmonary valve on the right side of the heart is far less common. When it does occur, it is usually congenital. A case report of combined calcific tricuspid and pulmonary stenosis illustrated how severe congenital pulmonary stenosis can raise right-sided pressures enough to cause secondary degeneration and calcification of the tricuspid valve.⁴

Congenital Causes and Bicuspid Aortic Valve

Not all stenosis develops with age. Some people are born with a valve that has the wrong number of leaflets. A bicuspid aortic valve, which has two leaflets instead of three, is the most common congenital heart defect in adults. It predisposes people to early aortic stenosis because the abnormal leaflets endure uneven stress and calcify decades sooner than a normal three-leaflet valve. The genetic roots of bicuspid valve disease remain mostly unknown for non-syndromic cases, but a genetic sequencing study of 272 patients who developed valve complications before age 30 found rare collagen gene variants in about 4% of them, representing a 30-fold enrichment compared with the general population.⁵ Some of those variants overlapped with connective tissue disorders, hinting that the valve defect can be part of a broader collagen problem.

Symptoms and When They Appear

Mild to moderate valve stenosis often produces no symptoms at all. You can carry a moderately narrowed aortic valve for years without knowing it, especially if you are not physically active enough to stress the heart. As the narrowing worsens, three classic symptoms tend to emerge: breathlessness, chest pain, and fainting.

Breathlessness develops because the stiffened heart muscle struggles to relax between beats. That impaired relaxation raises filling pressure in the heart and pushes fluid into the lungs.⁶ Chest pain can occur even without blocked coronary arteries, because the thickened muscle demands more oxygen than the blood supply can deliver, creating a mismatch between supply and demand.⁶

Fainting is perhaps the most alarming symptom. Patients who experience syncope with severe aortic stenosis tend to have a particular pattern: smaller valve openings, smaller heart chambers, and lower blood output per beat.⁷ Their hearts have remodeled in a way that leaves little room for error; any drop in filling pressure or spike in demand can abruptly cut blood flow to the brain. Once symptoms appear, the prognosis without treatment deteriorates quickly, which is why onset of any of these three symptoms typically triggers an urgent discussion about intervention.

Risk Factors That Speed Progression

Calcific aortic stenosis shares many risk factors with atherosclerosis. Smoking, high blood pressure, elevated cholesterol, and diabetes have all been linked to faster narrowing of the aortic valve.⁸ Smoking in particular has been consistently shown to accelerate the rate at which the valve area shrinks each year. Lipoprotein(a), a genetically influenced blood fat that most routine cholesterol panels do not measure, is now recognized as a valve-specific risk factor on top of the standard cardiovascular ones.⁹

The geographic pattern is striking. A global burden study found that calcific aortic valve disease peaks in high-income regions, with an age-standardized prevalence of about 350 per 100,000 people, while rheumatic heart disease dominates in low-income regions at roughly 1,184 per 100,000.¹⁰ In wealthier countries, the typical patient is an older adult with calcific disease; in poorer countries, it is a younger person with untreated strep throat that progressed to rheumatic damage.

Medical Treatment and Its Limits

There is no pill that can reverse a narrowed heart valve. In theory, drugs that target the biological pathways driving calcification should be able to slow progression, but no medication has been rigorously proven to do so.¹¹ Statin therapy seemed like a logical candidate given the overlap with atherosclerosis risk factors, but randomized trials of statins in aortic stenosis have been disappointing. Research continues into newer targets, including drugs aimed at the nitrous oxide pathway, vitamin K supplementation, colchicine (an anti-inflammatory), and repurposed diabetes medications.¹²

Standard heart failure medications present a particular challenge in severe stenosis. Blood pressure drugs like ACE inhibitors and calcium channel blockers can cause dangerous drops in blood pressure and fainting, because the fixed obstruction limits how much the heart can increase its output when pressure falls. Diuretics must be dosed carefully because these patients depend on adequate filling pressure to push blood past the obstruction. Beta-blockers risk weakening the pump further when there is already an outflow obstruction.¹³ In practice, medications serve mostly to manage symptoms and coexisting conditions while the patient awaits a procedure, or in cases where a procedure is not possible. They are not a substitute for fixing the valve.¹⁴

Surgical Valve Replacement

For decades, open-heart surgery to replace the diseased valve has been the definitive treatment for severe stenosis. The surgeon removes the damaged valve and sews in a prosthetic one, which is either mechanical (made from engineered materials and designed to last a lifetime) or bioprosthetic (made from animal tissue and eventually subject to wear). The choice between the two involves a genuine trade-off with no perfect answer.

Mechanical valves are durable but require lifelong blood-thinning medication, which raises the risk of bleeding and stroke. A meta-analysis pooling data from multiple studies found that patients with mechanical valves had a lower overall risk of death than those with bioprosthetic valves, but a higher rate of major bleeding.¹⁵ The survival advantage was clearest in the 50-to-70 age group, while patients older than 70 actually fared better with bioprosthetic valves, likely because the bleeding risk of lifelong anticoagulation outweighed the durability benefit.

For younger patients the picture is more decisive. A large study of over 109,000 valve replacements found that mechanical valves were associated with lower death rates in all age groups at or below 60.¹⁶ Bioprosthetic valves, on the other hand, carried a substantially higher risk of needing a second valve operation over the years, but offered significantly lower rates of stroke and bleeding.¹⁷ The conversation with your surgeon typically weighs your age, tolerance for blood thinners, lifestyle, and willingness to accept the possibility of a reoperation down the road.

Transcatheter Valve Replacement

Since the early 2010s, a less invasive option called transcatheter aortic valve replacement (TAVR, sometimes called TAVI) has transformed the landscape for aortic stenosis. Instead of open-heart surgery, a new valve is threaded up through a blood vessel in the groin and expanded inside the old valve. Initially reserved for patients too frail or too high-risk for surgery, TAVR has been tested in progressively lower-risk populations.

A randomized trial comparing TAVR to surgery in patients at low surgical risk found that TAVR was noninferior for death at one year, with roughly 5% versus 7% mortality. Major bleeding was substantially less frequent after TAVR than after surgery. However, TAVR came with a higher rate of vascular complications, a greater chance of needing a pacemaker afterward, and more valve leakage.¹⁸ That leakage concern is not trivial: at five years in an intermediate-risk trial, about a third of TAVR patients had at least mild leakage around the new valve, compared with about 6% after surgery. TAVR patients were also rehospitalized more often and needed more reinterventions.¹⁹

These five-year results help explain why TAVR has not simply replaced surgery across all age groups. For older adults who benefit from a shorter recovery and tolerate the higher leakage rates because they are less likely to outlive the valve, TAVR makes good sense. For younger, lower-risk patients, surgeons remain cautious about valve durability over decades, since TAVR valves are bioprosthetic and face the same eventual deterioration as surgical bioprosthetic valves, with the added uncertainty of a newer technology.

Balloon Valvuloplasty for Mitral Stenosis

When the problem is a narrowed mitral valve caused by rheumatic disease, the preferred approach in patients with pliable leaflets is percutaneous balloon valvuloplasty. A deflated balloon is guided through a vein into the heart and inflated inside the fused valve, splitting the stuck leaflets apart. This was first performed in 1984 and has since become the treatment of choice for suitable candidates.²⁰

The results are impressive for a procedure that avoids open-heart surgery entirely. A meta-analysis found that balloon valvuloplasty nearly doubles the mitral valve area on average and drops the pressure gradient across the valve substantially, while also reducing lung pressures.²¹ Complication rates compare favorably to surgical commissurotomy, with mortality under 1% and about a 1-2% risk of stroke.²⁰ However, the benefit is not permanent. A study tracking patients for five years after the procedure found an overall survival rate of about 76%, but only about half remained free from needing a repeat procedure, valve replacement, or cardiac death by the five-year mark.²² It buys time, sometimes years or decades, but the underlying disease process continues.

Stenosis in Children

Valve stenosis in children is overwhelmingly congenital. Aortic stenosis in an infant or young child often involves a bicuspid or even unicuspid valve, and the treatment decisions are different from those in adults. Children are still growing, so a fixed-size prosthetic valve will eventually be too small and need to be replaced again. This is where the Ross procedure comes in: the surgeon moves the child’s own pulmonary valve into the aortic position, then replaces the pulmonary valve with a donor valve. The native tissue has growth potential, avoids the need for blood thinners, and offers excellent blood flow characteristics.²³

The trade-off is real: you are turning single-valve disease into double-valve disease, because both the transplanted pulmonary valve and the donor valve replacing it can develop problems over time. Still, for pediatric patients the advantages tend to outweigh this risk, particularly because it delays or avoids the complications of mechanical valves in a growing child.²⁴ Case reports have even demonstrated feasibility in neonates with complex anatomy and active infection.²⁵

Heyde Syndrome and Unexpected Bleeding

Severe aortic stenosis can cause problems far from the heart. One of the stranger complications is Heyde syndrome, first described in 1958: a triad of aortic stenosis, an acquired bleeding disorder, and recurrent gastrointestinal bleeding. The mechanism was not understood until decades later. As blood squeezes through a severely narrowed aortic valve, the shearing forces physically shred large molecules of von Willebrand factor, a protein critical for blood clotting. The depleted clotting factor then allows fragile blood vessels in the gut to bleed repeatedly.²⁶ Patients sometimes undergo multiple endoscopies and cauterizations for intestinal bleeding before anyone connects the dots to their heart valve. Replacing the aortic valve restores normal shearing forces and allows von Willebrand factor levels to recover, often stopping the gut bleeding entirely.²⁷

Recovery and Cardiac Rehabilitation

Whether you have open surgery or a catheter-based procedure, recovery does not end when you leave the hospital. Cardiac rehabilitation programs that combine supervised exercise, nutritional guidance, smoking cessation support, and medication management have been shown to improve outcomes after valve procedures. A meta-analysis of exercise-based rehabilitation after TAVR found that participants significantly improved their walking distance, physical function scores, and mental health scores compared with baseline.²⁸

Prehabilitation, exercise and conditioning before the procedure, is gaining attention as well. Patients who go into valve replacement with better baseline fitness tend to recover faster and have fewer complications. No definitive guidelines exist yet for pre- and post-operative rehabilitation specifically tailored to valve replacement patients, but the existing evidence strongly favors enrolling in a supervised program when one is available.²⁹ If your cardiologist does not mention rehab, it is worth asking about it.